Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Mai on Barriers of Genetic Testing in CRC

January 13th 2021

Phuong L. Mai, MD, discusses barriers of genetic testing in colorectal cancer.

Addition of HIPEC to Cytoreductive Surgery in CRC Peritoneal Carcinomatosis Warrants Further Investigation

January 13th 2021

Prakash Pandalai, MD, discusses the role of HIPEC in CRC peritoneal carcinomatosis and data from the PRODIGE 7 and PROPHYLOCHIP-PRODIGE 15 trials.

Aggressive Treatment Approaches Expected to Move Dial in Metastatic Colon Cancer

January 13th 2021

Michael J. Cavnar, MD, highlights the role of surgery in colon cancer, the role of tumor sidedness in informing surgical decisions, and research efforts that are being done to evaluate the utility of hepatic artery infusion pumps.

Dr. Chalabi on the Role of MSI Testing in CRC

January 13th 2021

Myriam Chalabi, MD, discusses the utility of microsatellite instability (MSI) testing in colorectal cancer,

Adjuvant Oxaliplatin Added to Fluoropyridine Improves Survival in Stage III MSI-High Colon Cancer

January 12th 2021

The addition of adjuvant oxaliplatin to fluoropyridine improves overall survival and disease-free survival compared with fluoropyridine alone in patients with stage III colon cancer with microsatellite instability.

Dr. Chalabi on the Importance of Testing for MSI and dMMR in CRC

January 12th 2021

Myriam Chalabi, MD, highlights the importance of testing for microsatellite instability and mismatch repair deficiency in colorectal cancer.

Dr. Mai on Guidelines for Genetic Testing in CRC

January 8th 2021

Phuong L. Mai, MD, discusses guidelines for genetic testing in colorectal cancer.

Vemurafenib Plus Cetuximab/Irinotecan Improves PFS in BRAF-Mutant Metastatic CRC

January 6th 2021

January 6th, 2021 - The addition of vemurafenib to irinotecan and cetuximab led to a significant improvement in progression-free survival versus irinotecan and cetuximab alone in patients with BRAF V600E–mutated metastatic colorectal cancer.

Dr. Grothey on the Results of the ANCHOR-CRC Trial in BRAF V600E-Mutant mCRC

January 4th 2021

Axel Grothey, MD, discusses the results of the phase 2 ANCHOR-CRC trial in patients with BRAF-mutant metastatic colorectal cancer.

Pinpointing the Need for Genetic Testing in Oncology

December 31st 2020

Phuong L. Mai, MD, discusses the situations in which genetic testing should be considered and the importance of bridging awareness and access within oncology.

Oncolytics Biotech Launches Trial of Pelareorep/Atezolizumab Combo in Difficult-to-Treat GI Cancers

December 30th 2020

December 30, 2020 - The phase 1/2 GOBLET trial will investigate the use of pelareorep in combination with atezolizumab in patients with metastatic colorectal and advanced or metastatic pancreatic and anal cancers.

Dr. Cavnar on the Use of Hepatic Artery Infusion Pumps in CRC With Liver Metastases

December 22nd 2020

Michael J. Cavnar, MD, discusses the use of hepatic artery infusion pumps in patients with colorectal cancer with liver metastases.

Dr. Grothey on the DESTINY-CRC01 Trial With Trastuzumab Deruxtecan in HER2+ CRC

December 22nd 2020

Axel Grothey, MD, discusses the DESTINY-CRC01 trial in patients with HER2-positive colorectal cancer.

Dr. Eng on Future Research Efforts in Adjuvant CRC

December 21st 2020

Cathy Eng, MD, FACP, FASCO, discusses future research efforts in the adjuvant setting for colorectal cancer.

Dr. Kasi on Findings From the CRC-MRD Consortia in CRC

December 18th 2020

Pashtoon M. Kasi, MD, MS, discusses findings from the CRC-MRD Consortia in colorectal cancer.

Dr. Grothey on the Role of Precision Medicine in CRC

December 16th 2020

Axel Grothey, MD, discusses the role of precision medicine in colorectal cancer.

Dr. Cavnar on Surgical Differences Between Right- and Left-Sided Tumors in CRC

December 15th 2020

Michael J. Cavnar, MD, discusses surgical differences between right- and left-sided tumors in colorectal cancer.

Dr. Pandalai on the Development of Peritoneal Carcinomatosis in CRC

December 15th 2020

Prakash Pandalai, MD, discusses the development of peritoneal carcinomatosis in colorectal cancer.

Dr. Pandalai on the Use of Cytoreductive Surgery Plus HIPEC in Colorectal Peritoneal Carcinomatosis

December 15th 2020

Prakash Pandalai, MD, discusses the use of cytoreductive surgery plus heated intraperitoneal chemotherapy in the treatment of patients with colorectal peritoneal carcinomatosis.

Biomarkers Drive ICIs in Colon Cancer

December 14th 2020

December 14, 2020 - Immunotherapy agents have shown efficacy in malignant melanoma, kidney cancer, and non–small cell lung cancer, and investigators are examining the efficacy of checkpoint inhibitors in less immunogenic tumors such as colon cancer, particularly in tumors with high microsatellite instability and deficient mismatch repair genes.